KCNG4

Across TCGA pan-cancer cohorts, KCNG4 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated KCNG4 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher KCNG4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KCNG4 expression acts as an unfavorable survival marker.

OV, STAD, and PRAD are the cancer types where KCNG4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.140	0.541	.001	18	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	DFS	Median	All	0.156	0.753	<.001	6	view →
BLCA	OS	Median	All	0.228	0.720	.034	6	view →
LIHC	OS	Median	All	0.098	0.774	.001	6	view →
BRCA	DFS	Median	All	0.734	0.903	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

KCNG4–OV (DFS)

Open the OV breakdown →